Aderhold Neuroleptika minimieren 6.0 - BGSP

31Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J; CLAMORS Study Collaborative Group. (2007):Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORSStudy. Schizophr Res. 90(1-3):162-73.Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ.(2006): Hyperlipidemia following treatment withantipsychotic medications. Am J Psychiatry. 163(10):1821-5.Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Järvelin MR, Laurén LH, Savolainen MJ, Koponen HJ.(2005). A 4-fold riskof metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J Clin Psychiatry.66(5):559-63Suvisaari JM, Saarni SI, Perälä J, Suvisaari JV, Härkänen T, Lönnqvist J, Reunanen A.(2007): Metabolic syndrome amongpersons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry 68(7):1045-55.Wetterling T, Schneider B, Weber B.(2007): Dyslipidemie and Schizophrenie. Psychiatr Prax. 34(5):223-9.Strassnig M, Miewald J, Keshavan M, Ganguli R.(2007): Weight gain in newly diagnosed first-episode psychosis patientsand healthy comparisons: one-year analysis. Schizophr Res. 93(1-3):90-8.91 Neuhauser H, Ellert U: Prävalenz des metabolischen Syndroms in Deutschland: eine Sensitivitätsanalyse, MeetingAbstract, 50. gmds Tagung, German Medical Science; 2005.Moebus S, Hanisch J, Neuhäuser M, Aidelsburger P, Wasem J, Jöckel KH (2006) Prävalenz des Metabolischen Syndroms ineiner deutschlandweiten Querschnittsstudie in 1511 hausärztlichen Praxenhttp://www.gmds2006.de/Abstracts/361.pdf92 Ford ES, Giles WH, Dietz WH. Prevalence of the Metabolic Syndrome Among US Adults. JAMA 2002;287:356-35993 Weiser M, Knobler H, Lubin G, Nahon D, Kravitz E, Caspi A, Noy S, Knobler HY, Davidson M.(2004): Body mass indexand future schizophrenia in Israeli male adolescents. J Clin Psychiatry. 65(11):1546-9.94 Jin H, Meyer JM, Jeste DV.(2004): Atypical antipsychotics and glucose dysregulation: a systematic review. SchizophrRes. 2004 Dec 1;71(2-3):195-212.Newcomer JW.(2005): Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literaturereview. CNS Drugs. 19 Suppl 1:1-93.95Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L.(2003): A retrospective cohort study of diabetesmellitus and antipsychotic treatment in the United States. J Clin Epidemiol. 56(2):164-70.Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA.(2003):Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings froma large health plan database. J Clin Psychiatry. 63(10):920-30.96 Correll CU, Frederickson AM, Kane JM, Manu P.(2006): Metabolic syndrome and the risk of coronary heart disease in 367patients treated with second-generation antipsychotic drugs. J Clin Psychiatry. 67(4):575-83.97 Expert Panel on the Diagnosis and Classification of Diabetes Mellitus, 2004. Diagnosis and classification of diabetesmellitus. Diabetes Care 27, S5– S10.98Gerstein HC, Pais P, Pogue J, Yusuf S.(1999) Relationship of glucose and insulin levels to the risk of myocardialinfarction: a case-control study. J Am Coll Cardiol. 33(3):612-9.99 Coutinho M, Gerstein HC, Wang Y, Yusuf S.(1999): The relationship between glucose and incident cardiovascularevents. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years.Diabetes Care. 22(2):233-40.100 Jin H, Meyer JM, Jeste DV.(2004): Atypical antipsychotics and glucose dysregulation: a systematic review. SchizophrRes. 2004 Dec 1;71(2-3):195-212.101 Expert Panel on the Diagnosis and Classification of Diabetes Mellitus, 2004. Diagnosis and classification of diabetesmellitus. Diabetes Care 27, S5– S10.